PF4 and scleroderma: However, when we concentrate the analysis on patients with more active disease (disease index >3), we could see a consistent correlation between the level of antibody response to CXCL4 and disease score, as measured by the European Scleroderma Study Group Activity Index (EScSGAI [17]) (Figure 2a).